Skip to content

A Study on the Application of Near-Infrared Brain Functional Imaging Technology in Cognitive Stimulation Therapy for Mild to Moderate Dementia

A Study on the Application of Near-Infrared Brain Functional Imaging Technology in Cognitive Stimulation Therapy for Mild to Moderate Dementia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118654
Enrollment
Unknown
Registered
2026-02-09
Start date
2024-03-15
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease,Dementia

Interventions

Study Group:(1) Both groups routinely used cholinesterase inhibitors. Both groups could administer low-dose antipsychotic medications such as risperidone or quetiapine based on patients' psychotic and
Control Group: Both groups routinely used cholinesterase inhibitors. Both groups could administer low-dose antipsychotic medications such as risperidone or quetiapine based on patients' psychotic and

Sponsors

Chongqing Mental Health Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Healthy male and female subjects aged 60 to 85 years (including 60 and 85 years); 2. Meet the clinical description and diagnostic criteria for Alzheimer's disease and vascular dementia as defined in the International Classification of Diseases, Tenth Revision (ICD-10); 3. Mini-Mental State Examination (MMSE) score between 10 and 24; 4. All patients exhibit significant neuropsychiatric symptoms, with a BEHAVE-AD score =8 points. 5. No significant hearing or visual impairment; capable of simple communication and willing to undergo assessment after thorough explanation. 6. Family members fully understand the trial and provide signed informed consent prior to screening; 7. No severe physical illnesses.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications to cholinesterase inhibitors or antipsychotic medications; 2. Patients who request discontinuation due to adverse events; 3. Patients who withdraw informed consent; 4. Patients whose treatment is interrupted after enrollment due to non-drug-related causes such as severe physical illness; 5. Patients deemed ineligible for enrollment by the investigator.

Design outcomes

Primary

MeasureTime frame
Alzheimer’s disease assessment scale, ADAS-cog;

Secondary

MeasureTime frame
Quality of Life–Alzheimer’s Disease ;Activity of Daily Living Scale;Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD);Clinical Global Impression (CGI) Scale;Mini-Mental State Examination (MMSE);oxyhemoglobin;deoxy hemoglobin;

Countries

China

Contacts

Public ContactZhao Xinmin

Chongqing Mental Health Center

zing159@163.com+86 137 5297 5637

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 28, 2026